Amir Mehrvarz Sarshekeh, MD
Hematology & Oncology · Everett, WANPI 1649697707
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 3 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Regeneron Healthcare Solutions, Inc. accounts for 90.9% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2024 at $88 and has fallen 82.0% since, to $16 in 2025. That places this record below the midpoint for hematology & oncology clinicians in WA, where the typical reported total is $899.
Across 3 payments — averaging $58.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$160
- Novartis$16
Across 23 payments — averaging $7927.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$168K
- Seagen Inc.$14K
What the payments were for
- Food & beverage$176100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 2 | $160 |
| Novartis | 1 | $16 |
How this compares
$176 in reported general payments places this provider in the 25th percentile of 349 hematology & oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 39 | $641,580 |
| XtandiEnzalutamide | 32 | $497,196 |
| Lenalidomide | 32 | $493,669 |
| RevlimidLenalidomide | 16 | $354,446 |
| NubeqaDarolutamide | 26 | $340,298 |
| PomalystPomalidomide | 14 | $327,023 |
| CabometyxCabozantinib S-Malate | 11 | $300,446 |
| ErleadaApalutamide | 15 | $237,978 |
| BrukinsaZanubrutinib | 16 | $231,560 |
| IbrancePalbociclib | 12 | $187,953 |
| JakafiRuxolitinib Phosphate | 11 | $147,587 |
| Abiraterone Acetate | 48 | $54,735 |
| XareltoRivaroxaban | 15 | $20,086 |
| EliquisApixaban | 20 | $18,392 |
| Hydroxyurea | 51 | $1,782 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Everett
- Xiaowen WangEverett$33K
- John PesandoSeattle$15.7M
- Jill JohnsenSeattle$991K
- Fengting YanSeattle$841K
- John PagelSeattle$725K
- Lawrence FongSeattle$546K
- Langdon MillerSeattle$457K
- Mazyar ShadmanSeattle$226K
- Catherine LeeSeattle$199K
- Thomas BoydSpokane$187K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.